Avisi Technologies

• 26/02/2026
• Series A
• $10,700,000

Avisi is developing a portfolio of ophthalmic treatments based on a novel metamaterial technology. Its flagship product, VisiPlate, is a nanotechnology-enabled implant to treat glaucoma.

Glaucoma is the leading cause of irreversible blindness in the world and currently has no cure.

To date, Avisi has been supported by venture investors as well as grants and awards from: the National Science Foundation, the University of Pennsylvania, Wharton, The School of Engineering and Applied Science, Penn Law's Entrepreneurship Legal Clinic, the Singh Center for Nanotechnology, and VentureWell. Avisi has been recognized as the winner of the Ophthalmology Technology Summit People’s Choice Award, the Winner of the Glaucoma Research Foundation H. Dunbar Hoskins International Innovations Award, a finalist of the 2022 FIERCE Life Sciences Innovation Awards, one of ten most promising Philadelphia tech companies of the decade in Technical.ly’s RealLIST Startups 2020, a Watchlist venture in Wharton Magazine, and a finalist at the 2019 SXSW Innovation Awards for Health, Med, and Biotech.

Avisi is a proud member/alum of Johnson & Johnson JLABS incubator, UCSF Rosenman Innovators, OC OCTANE LaunchPad, and MedTech Innovator Accelerator.

Website: www.avisitech.com
Twitter: @avisi_tech

---

---